Comparative Pharmacology
Head-to-head clinical analysis: CLOFARABINE versus IMKELDI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOFARABINE versus IMKELDI.
CLOFARABINE vs IMKELDI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.
Imkelde (imipenem/cilastatin/relebactam) is a combination antibacterial agent. Imipenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Cilastatin inhibits renal dehydropeptidase I, preventing renal metabolism of imipenem. Relebactam is a beta-lactamase inhibitor that protects imipenem from degradation by certain serine beta-lactamases, including KPC and some AmpC enzymes.
52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.
10 mg orally once daily
None Documented
None Documented
Clinical Note
moderateClofarabine + Digoxin
"Clofarabine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateClofarabine + Digitoxin
"Clofarabine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateClofarabine + Deslanoside
"Clofarabine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateClofarabine + Acetyldigitoxin
"Clofarabine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life: 5.2 hours (range 4-6 hours) in adult patients; clinically, this supports a 5-day continuous infusion schedule
Terminal elimination half-life: 12 hours (range 10-14 hours) in healthy adults; extended to 24-30 hours in moderate renal impairment (CrCl 30-50 mL/min). Clinical context: Steady state achieved after 3-4 days. Twice-daily dosing maintains therapeutic levels.
Renal: 49-60% as unchanged drug; biliary/fecal: minimal (<1%)
Primarily renal excretion of unchanged drug and metabolites; 70% recovered in urine (60% unchanged, 10% as glucuronide conjugate) and 30% in feces (mainly metabolites) over 72 hours.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent